• 3-Deazaadenosine hydrochloride in SAHH Studies

  2026-09-08

  3-Deazaadenosine hydrochloride provides an upstream way to perturb SAHH-dependent methyl metabolism while researchers measure RNA stability, hepatic stellate cell activation, and fibrosis-associated phenotypes. This guide connects that biochemical lever to the IGF2BP1–TUBB4B–FAK model and offers practical dosing, controls, and troubleshooting strategies.

• VERTIS CV: Ertugliflozin and Cardiovascular Outcomes

  2026-09-08

  The VERTIS CV trial established cardiovascular noninferiority for ertugliflozin versus placebo in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, while not demonstrating superiority for its key heart-failure composite. Its randomized event-driven design provides a useful framework for interpreting safety, renal signals, subgroup applicability, and the distinction between noninferiority and cardiovascular benefit.

• High-Throughput BBB Permeability: Study Insights

  2026-09-07

  Hu and colleagues developed a Transwell surrogate blood-brain barrier model that pairs LLC-PK1-MOCK and LLC-PK1-MDR1 cells with bidirectional transport measurements and lysosomal trapping correction. The platform showed strong agreement between in vitro permeability and unbound brain distribution, supporting more mechanism-aware prioritization of CNS drug candidates.

• Caspofungin Workflows for Candida Research

  2026-09-07

  Caspofungin is a benchmark lipopeptide antifungal drug for studying glucan synthase inhibition, azole-resistant Candida, and cell-wall vulnerability. This practical guide converts its mechanism and comparative performance into reproducible susceptibility, mechanistic, and translational workflows.

• PF-573228: FAK Inhibitor Workflow Guide

  2026-09-05

  PF-573228 is a potent ATP-competitive FAK inhibitor for dissecting adhesion, mechanotransduction, migration, and survival. This workflow translates stiffness-dependent dentinogenesis findings into practical phospho-FAK, mineralization, cancer-cell, and endothelial assays while emphasizing dose selection and controls.

• YY1 Mutations Rewire Cortical Development

  2026-09-04

  A bioRxiv study integrates patient-derived 2D and 3D neural models with imaging, single-cell multiomics, and gene regulatory network reconstruction to define how YY1 haploinsufficiency disrupts corticogenesis in Gabriele-de Vries syndrome. Its key advance is the separation of cell-autonomous defects in progenitors and neurons from neuron-driven, non-cell-autonomous inflammatory changes in neighboring astrocytes, providing a mechanistic framework for future interventions.

• Sulfo-NHS-LC-Biotin: Practical Labeling Guide

  2026-09-04

  Sulfo-NHS-LC-Biotin is a water-soluble reagent for covalent biotin labeling of primary amines on proteins, peptides, and accessible cell-surface proteins. It is appropriate for stable extracellular or purified-protein workflows, but not for reversible labeling or modification of intracellular targets in intact cells.

• Artesunate: Cancer Assay Workflows

  2026-09-03

  Use Artesunate to distinguish growth suppression from true cancer-cell killing in controlled in vitro experiments. This workflow combines solvent-aware dosing, orthogonal viability measurements, and mechanism-focused follow-up for small cell lung carcinoma and esophageal squamous cell carcinoma models.

• Metoprolol Tartrate: Selectivity as an Assay Variable

  2026-09-03

  Metoprolol Tartrate is more than a cardioselective beta blocker: it is a useful experimental control for separating β1-dependent cardiac effects from broader sympathetic signaling. This article translates transplant-regeneration evidence into a selectivity-centered framework for cardiovascular research, hypertension research, and hematopoietic assays.

• Shrimp STING Reveals an Ancestral DNA-Sensing Axis

  2026-09-02

  The reference study shows that Litopenaeus vannamei STING can bind cytosolic double-stranded DNA as well as cyclic dinucleotides and activate an IFN-like antiviral program. By connecting ligand recognition to IKKε–IRF signaling and Vago4 induction, the work provides evidence that direct STING-mediated DNA sensing predates the better-characterized vertebrate pathway.

• Hesperadin: Aurora B Kinase Inhibitor Workflow

  2026-09-02

  Hesperadin provides a practical perturbation strategy for linking Aurora B signaling to histone H3 phosphorylation, chromosome missegregation, cytokinesis failure, and polyploidization. This workflow distinguishes Aurora B phenotypes from the Polo-like kinase 1 checkpoint-disassembly mechanism described in the reference study, improving interpretation in cell cycle and cancer research.

• nor-Binaltorphimine dihydrochloride for KOR Studies

  2026-09-01

  Use nor-Binaltorphimine dihydrochloride to test whether spinal κ-opioid receptor signaling controls the spread and persistence of mechanical allodynia. This workflow combines bilateral behavioral profiling, carefully matched vehicle controls, and circuit-level validation for more informative opioid receptor pharmacology.

• Merbromin Inhibits SARS-CoV-2 3CLpro

  2026-09-01

  The reference study identifies merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 3CLpro/Mpro protease through enzyme-based high-throughput screening, kinetic analysis, binding assays, and molecular docking. Its comparison with Proteinase K, trypsin, and papain supports a degree of target selectivity and provides a biochemical scaffold for future inhibitor development, while stopping short of demonstrating cellular or clinical antiviral efficacy.

• Sulfo-NHS-LC-Biotin: Practical Protein Labeling Guide

  2026-08-31

  Sulfo-NHS-LC-Biotin provides water-compatible, irreversible biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suited to streptavidin-based detection, capture, and surface-protein workflows, but not to reversible chemistry or intracellular labeling in intact cells.

• AI-10-49: From Fusion Target to AML Strategy

  2026-08-31

  AI-10-49 offers a mechanism-led approach to inv(16) acute myeloid leukemia research by disrupting the CBFβ-SMMHC–RUNX1 interaction. This article connects target engagement, RUNX1 chromatin occupancy, the MYCN/eIF4G1 survival axis, and translational study design into a practical strategy for evaluating a selective leukemia inhibitor.

8722 records 2/582 page Previous Next 12345 下5页 Last page